RHB has lowered its target price for Raffles Medical to S$1.50 from S$1.55, even as it maintains its “buy” rating on the healthcare group.

RHB Group Research analyst Shekhar Jaiswal has kept his “buy” call on Raffles Medical with a lower target price of $1.50 from $1.55 previously.In his view, China’s Covid-19-related lockdowns could still impact the group’s operations in the country.“[The impact] could still be visible in [R...

Maintaining the barbell approach recommended by analysts is proving heavy this year.Singapore investors not only have to contend with new waves of Covid-19 in July, as warned by health minister Ong Ye Kung, but also consider a host of worries abroad.RHB Group Research analyst Shekhar Jaiswal lists t...

RHB Group Research analyst Shekhar Jaiswal reiterates a barbell portfolio strategy recommendation with a mix of growth and defensive Singapore equities for 2QFY2022 amid the country’s reopening of international borders and the domestic economy.Although the reopening as well as the government’s a...

Global Alpha Capital Management has increased its deemed stake in Raffles Medical Group. On May 5, the Montreal-based fund manager paid $1.21 each for 761,300 shares on the open market, raising its total holdings to just over 148.9 million shares, equivalent to 8.017%, up from 7.976% previously.Glob...

Singapore’s reopening continues to gain ground, says CGS-CIMB Research analyst Lock Mun Yee, putting SIA Engineering Company (SIAEC), Singapore Post (SingPost) and SingTel in good stead for the coming months.“Sectors that will benefit include retail and office landlords, transport and those tour...

RHB Group Research analyst Shekhar Jaiswal is recommending investors have a mix of growth and defensive in their Singapore portfolio amid the current inflationary environment and the geopolitical uncertainties.“For 2Q2022, Singapore’s equity market outlook will continue to depend on how well sto...

Investors in Singapore equities should maintain a balanced portfolio in 2Q2022. Despite reopening, risks are aplenty, says RHB Group Research analyst Shekar Jaiswal.“For 2Q2022, Singapore’s equity market outlook will continue to depend on how well stocks and sectors deal with: uncertainty over t...

As the Chinese healthcare authority looks into the impact of listed for-profit medical institutions on the development of healthcare in the country, investors are concerned that the interest in the sector may spark another crackdown, similar to that of the Chinese education sector. According to the ...

FOR the 5 trading sessions that spanned Mar 4 to 10, the Straits Times Index (STI) declined 0.4 per cent, with the FTSE China A50 Index falling 5.6 per cent, the Hang Seng Index dropping 6.7 per cent and the FTSE Bursa Malaysia KLCI slipping 2.2 per cent.